Compare Nokia Corp (NOK) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nokia Corp vs Twist Bioscience Corp — how do they compare? Nokia Corp trades at $10.34 (market cap $56.99B), while Twist Bioscience Corp trades at $159.69 (market cap $10.08B). The key difference: Nokia Corp is far larger — about 5.7× Twist Bioscience Corp's market cap, and Nokia Corp pays a 1.61% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nokia Corp for 66 Days and Twist Bioscience Corp for 27 Days on average.
| NOK | TWST | |
|---|---|---|
Market Cap | $56.99B | $10.08B |
Volume | 69,968,204 | 4,229,037 |
Sector | Technology | Health |
52-Week High | $16.83 | $205.00 |
52-Week Low | $5.18 | $25.45 |
Typical Hold Time | 66 Days | 27 Days |
Enterprise Value | $55.01B | $10.01B |
Dividend Yield | 1.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nokia (NOK) trades at $10.62, down 3.19% on the day, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $19.89 billion with a net income margin of 3.47%. Recent news highlights a strategic partnership with Microsoft for AI-driven network automation and sovereign satellite network development with ICEYE, positioning Nokia for growth in AI and telecommunications infrastructure.
The outlook for Nokia is positive, supported by strong analyst consensus with a $17.50 price target and 61.5% buy ratings. Key opportunities include expanding AI and cloud orders, which grew 105% in Q2 2026. Risks involve competitive pressures in telecom equipment, reliance on global infrastructure spending, and volatility in net cash flow, which turned negative in 2025. Execution on partnerships and margin expansion are critical for sustained upside.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
